<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2403257146
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Amilian
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMISULPRIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        60.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="(Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 437]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group: Antipsychotics, ATC code: N05AL05 Amilian belongs to a group of medicines known as antipsychotics. This medicine is used to treat people with schizophrenia. Schizophrenia is a mental illness characterised by various mental and behavioral disorders, such as hallucinations or agitation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Amilian:</strong></p><p>- if you are allergic to the active substance (amisulpride) or any of the other ingredients of this medicine (listed in section 6).</p><p>- if you have a pheochromocytoma (excessive growth of the adrenal glands around the kidneys, releasing substances which cause high blood pressure).</p><p>- in children under 15 years of age.</p><p>- if you have a prolactin-dependent tumour (prolactin is a hormone that stimulates milk production), e.g. breast cancer or pituitary disorders.</p><p>- if you are taking other medicines. If this is the case, make sure that combined use with Amilian is not contraindicated (see &ldquo;Other medicines and Amilian &rdquo;).</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Amilian. Your doctor may ask you to have an electrocardiogram (ECG) before starting treatment. This medicine can cause heart rhythm disorders (see section 4). This medicine should be used with caution in the following situations:</p><p>-In elderly patients, particularly if they have dementia, because of the risk of a drop in blood pressure and of drowsiness; if the patients have kidney failure your doctor may reduce the dose</p><p>-If you have risk factors for stroke, which occurs when the blood flow is abruptly interrupted in part of the brain.</p><p>-If you or a family member have a history of blood clots, since taking antipsychotic drugs may cause blood clots to form.</p><p>-If you have kidney disease (kidney failure), in which case your doctor may reduce the dose.</p><p>-If you have epilepsy or Parkinson&rsquo;s disease.</p><p>-If you have diabetes or if you have risk factors for diabetes</p><p>-If you have a history of hyperprolactinemia (too much prolactin in the blood) or a prolactin- dependent tumour (prolactin is a hormone that stimulates milk production), e.g. breast cancer or pituitary disorders. If this is the case, your doctor will have to monitor you closely during treatment.</p><p>Serious liver problems have been reported with Amilian. Tell your doctor immediately if you experience tiredness, loss of appetite, nausea, vomiting, abdominal pain or yellowing of the eyes or skin.</p><p>If during treatment, you develop muscle stiffness and consciousness disorders, along with an unexplained fever, stop treatment immediately and contact your doctor straight away.</p><p>If during treatment, you develop visual disturbances or headaches, consult your doctor quickly.</p><p>If you develop an infection or unexplained fever, your doctor may have you undergo a blood test immediately. This is because this medicine may have an effect on your blood cells, i.e. reduce the number of white blood cells. This problem can be seen in a blood test (see section 4, &ldquo;Possible side effects&rdquo;).</p><p>Treatment with this medicine should not be suddenly stopped because this can cause a withdrawal syndrome. This is characterised by signs such as insomnia, nausea and vomiting. Abnormal movements may also be observed and psychotic disorders recur.</p><p><strong>Children and adolescents:</strong></p><p>-This medicine should not be given to children under 15 years of age.</p><p>-Use of this medicine is not recommended in children between 15 and 18 years of age.</p><p><strong>Other medicines and Amilian.</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or may take any other medicines.</p><p>You must not take this medicine with cabergoline, quinagolide (medicines used to treat milk production disorders), citalopram or escitalopram (medicines used to treat anxiety or depression), domperidone (medicine used to treat nausea and vomiting), hydroxyzine (medicine used to treat anxiety or hives) or piperaquine (medicine used to treat malaria).</p><p>You must avoid taking this medicine with:</p><p>-Some medicines used to treat Parkinson&rsquo;s disease (amantadine, apomorphine, bromocriptine, entacapone, lisuride, pergolide, piribedil, pramipexole, rasagiline, ropinirole, rotigotine, selegiline, tolcapone).</p><p>- Levodopa.</p><p>- Sodium oxybate (medicine used to treat narcolepsy).</p><p>- Some medicines which may cause serious heart rhythm disorders (called &ldquo;torsades de pointes&rdquo;) such as:</p><p>&bull; Medicines used to treat irregular heartbeat (class Ia antiarrhythmics such as quinidine, hydroquinidine, disopyramide and class III antiarrhythmics such as amiodarone, dronedarone, sotalol, dofetilide and ibutilide)</p><p>&bull; Some medicines used to treat psychiatric disorders (chlorpromazine, cyamemazine, droperidol, flupenthixol, fluphenazine, haloperidol, levomepromazine, pimozide, pipamperone, pipotiazine, sulpiride,sultopride, tiapride, zuclopenthixol)</p><p>&bull; Some antiparasitic agents (chloroquine, halofantrine, lumefantrine, pentamidine)</p><p>&bull; A medicine used to treat dependence on some drugs (methadone)</p><p>&bull; Other medicines such as: arsenic compounds, diphemanil, dolasetron IV, erythromycin IV, hydroxychloroquine, levofloxacin, mequitazine, mizolastine, prucalopride, vincamine IV, moxifloxacin, spiramycin IV, toremifene, vandetanib</p><p>- Medicines containing alcohol.</p><p><strong>Amilian with food, drink and alcohol </strong></p><p>As with all antipsychotic drugs in this group, you must avoid drinking alcoholic beverages during treatment.</p><p><strong>Pregnancy, breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Pregnancy</strong></p><p>Amilian is not recommended during pregnancy or in women of childbearing potential who are not using effective contraception. If you use Amilian during the last 3 months of your pregnancy, your baby may experience agitation, increased muscle stiffness, involuntary trembling, drowsiness, breathing problems or difficulty feeding or suckling. If your baby has any of these symptoms, contact your doctor quickly.</p><p><strong>Breast-feeding</strong></p><p>You must not breast-feed during treatment with Amilian. Ask your doctor about the best way to feed your baby if you are taking Amilian. Driving and using machines This medicine can cause drowsiness and blurred vision. You must take care if you drive a vehicle or use machines.</p><p><strong>Amilian contains lactose</strong></p><p>This medicine contains a type of sugar (lactose) that is broken down into galactose and glucose. You should not use this medicine if you have galactose intolerance, Lapp lactase deficiency or glucose/ galactose malabsorption syndrome (rare hereditary diseases). If your doctor has told you that you have an intolerance to certain sugars, contact him/her before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. Check with your doctor or pharmacist if you are not sure.</p><p>Do not stop the treatment of your own accord.</p><p>This medicine should be taken by mouth.</p><p>Swallow the tablet(s) with a small amount of water.</p><p><strong>If you take more Amilian than you should</strong></p><p>You may experience drowsiness, sedation (a relaxing effect), a drop in blood pressure, extrapyramidal symptoms (particularly trembling and muscle stiffness) or you may fall into a coma. If any of these occur, it is absolutely essential that you or your family/ friends call a doctor or the emergency medical services.</p><p><strong>If you forget to take Amilian</strong></p><p>Do not take a double dose to make up for a forgotten dose. Take the following dose at the usual time.</p><p>If you have forgotten several doses, ask your doctor for advice.</p><p><strong>If you stop taking Amilian</strong></p><p>Not applicable.</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse, or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If, during treatment, you develop muscle stiffness and consciousness disorders, along with an unexplained fever, stop treatment immediately and seek urgent medical attention.</p><p>The following side effects are very common (affecting more than 1 patient in 10):</p><p>trembling, muscle stiffness, cramps, abnormal movements, producing more saliva than usual.</p><p>The following side effects are common (affecting 1 to 10 patients in 100):</p><p>- Stiff neck, oculogyric crises (abnormal movement of certain eye muscles), intense contraction of jaws</p><p>- Drowsiness</p><p>- Insomnia, anxiety, agitation</p><p>- Constipation, nausea, vomiting, dry mouth</p><p>- Frigidity (lack of sexual pleasure in women)</p><p>- Hyperprolactinemia (too much prolactin, the hormone that induces milk production, in the blood), which may cause:</p><p>&bull; in women: absence of menstrual periods, abnormal production of breast milk, breast pain</p><p>&bull; in men: swelling of breasts, impotence (erection difficulties)</p><p>- Weight gain</p><p>- Low blood pressure (hypotension)</p><p>- Blurred vision.</p><p>The following side effects are uncommon (affecting 1 to 10 patients in 1 000):</p><p>- Involuntary movements of the tongue and/or face</p><p>- Seizures (involuntary contractions of one or more muscles)</p><p>- Hyperglycaemia (too much sugar in the blood)</p><p>- Hypertriglyceridemia (too much fat (triglycerides) in the blood)</p><p>- Hypercholesterolaemia (too much cholesterol in the blood)</p><p>- Slow heartbeat -</p><p>Increased levels of certain liver enzymes, mainly transaminases</p><p>- Liver tissue injury</p><p>- Reduced bone density or change in bone structure (osteopenia, osteoporosis), weakening the bones</p><p>- Allergic reactions</p><p>- Confusion</p><p>- Stuffy nose</p><p>- Lung disorders (aspiration pneumonia) that may appear as inflammation, difficulty breathing, an infection, cough (mainly in combination with other drugs with a central nervous depressant effect)</p><p>- Increase in blood pressure</p><p>- Difficulty urinating</p><p>- Leukopenia, neutropenia (see section 2, paragraph &ldquo;Warnings and precautions&rdquo;).</p><p>The following side effects are rare (affecting 1 to 10 patients in 10 000):</p><p>- Agranulocytosis (a low level of white blood cells) (see section 2, &ldquo;Warnings and precautions&rdquo;)</p><p>- Benign pituitary tumour, which may cause signs such as visual disturbances or headaches</p><p>- Drop in the amount of sodium in the blood (hyponatremia), syndrome of inappropriate antidiuretic hormone secretion</p><p>- Unexplained fever, along with general and neurological disorders</p><p>- Serious fainting (loss of consciousness), heart rhythm disorders possibly causing death (see section 2)</p><p>- Swelling, pain and redness of the legs. This is because blood clots in the veins (particularly in the legs) can move through blood vessels to reach the lungs, causing chest pain and difficulty breathing</p><p>- Sudden swelling of the face and/or neck that can lead to difficulty breathing and may be life- threatening (angioedema), red, itchy patches on the skin (hives).</p><p>The following side effects may occur, but their frequency is not known:</p><p>- Withdrawal syndrome in newborn infants (see section 2, &ldquo;Pregnancy&rdquo;)</p><p>- Restless legs syndrome (uncomfortable feeling in the legs that is temporarily relieved by movement, and is worse at the end of the day)</p><p>- Increased skin sensitivity when exposed to sun and ultraviolet rays.</p><p>- Falls due to loss of balance, which may involve fractures.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, nurse, or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date which is stated on the carton and label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</li><li>Store below 30&deg; C</li><li>Do not throw away any medicines via wastewater or household waste.</li></ul><p>Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Amilian contains:</p><p>The active substance is: Amisulpride</p><ul><li>Each Amilian 100 mg tablet contains 100 mg of Amisulpride.</li><li>Each Amilian 200 mg tablet contains 200 mg of Amisulpride.</li><li>Each Amilian 400 mg tablet contains 400 mg of Amisulpride.</li></ul><p><strong>The other ingredients are:&nbsp;</strong><br />Microcrystalline cellulose<br />Lactose monohydrate<br />Sodium starch Glycolate<br />Hydroxypropyl Methyl cellulose<br />Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Amilian 400 mg Tablets: White to off-white, Capsule shape, biconcave 
uncoated tablets scored on one side and plain on other side.
Amilian 200 mg Tablets: White to off-white, round flat faced uncoated 
tablet scored on one side and plain on other side.
Amilian 100 mg Tablets: White to off-white, round flat faced uncoated 
tablet plain on both sides.
Amilian 100mg, 200mg and 400mg are available in blister packs of 
30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Middle East Pharmaceutical Industries Company (Avalon Pharma), P.O.Box 4180 Riyadh 11491, 2nd Industrial City, Riyadh, Kingdom of Saudi Arabia Tel: +966 (11) 2653948 -2653427 Fax: +966 (11) 2654723</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was approved in [05/2024]
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المجموعة الدوائية العالجية: مضادات الذهان، رمز نظام التصنيف الكيميائي العالجي التشريحي: 05AL05N، ينتمي أميليان إلى مجموعة من األدوية معروفة باسم مضادات الذهان. ّسم بالعديد من ُستخدم هذه األدوية في عالج مرضى الفصام. والفصام هو مرض عقلي يت ت االضطرابات العقلية والسلوكية، مثل الهلوسات أو االهتياج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أميليان في الحالات التالية:</p><p dir="RTL">- إذا كنت تعاني من الحساسية ضد المادة الفعَّالة )أميسولبرايد( أو أيٍّ من المكونات الأخرى لهذا الدواء )والمذكورة في القسم .(6</p><p dir="RTL">- إذا كنت تعاني من ورم القواتم )نمو مفرط للغدة الكظرية حول الكليتين التي تُفرز المواد التي تسبب ارتفاع ضغط الدم.(</p><p dir="RTL">- الأطفال الأقل من 15 عامًا.</p><p dir="RTL">- إذا كنت تعاني من ورم يعتمد على البرولاكتين )البرولاكتين هو هرمون يحفز إنتاج الحليب( على سبيل المثال: سرطان الثدي أو اضطرابات الغدة النخامية.</p><p dir="RTL">- إذا كنت تتناول أدوية أخرى. في هذه الحالة، تأكد من أن استخدام أميليان لا يتعارض مع استخدام أدوية أخرى )انظر &laquo;الأدوية الأخرى وأميليان.(&raquo;</p><p>&nbsp;</p><p>تحذيرات واحتياطات</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي قبل تناول أميليان في الحالات التالية :</p><p>&nbsp;</p><p dir="RTL">قد يطلب منك طبيبك إجراء مخطط كهربية القلب قبل بدء العلاج. ويمكن لهذا الدواء أن يسبب اضطرابات في ضربات القلب )انظر القسم .(4</p><p>&nbsp;</p><p dir="RTL">يجب استخدام هذا الدواء بحذر في الحالات الآتية:</p><p dir="RTL">- المرضى من كبار السن، إذا كانوا يعانون من خرف الشيخوخة، بسبب خطر الإصابة بانخفاض ضغط الدم والنعاس. وإذا كان المرضى يعانون من الفشل الكلوي، فقد يقوم الطبيب بتقليل الجرعة.</p><p dir="RTL">- إذا كنت تعاني من عوامل خطر الإصابة بالسكتة الدماغية، والتي تحدث عندما ينقطع تدفّق الدم بشكل مفاجئ عن جزء من الدماغ.</p><p dir="RTL">- إذا كان لديك أو لدى أحد أفراد أسرتك تاريخ من الإصابة بجلطات الدم، حيث قد يؤدي تناول الأدوية المضادة للذهان إلى تكوين جلطات دموية.</p><p dir="RTL">- إذا كنت تعاني من مرض الكِلَى )الفشل الكلوي(، في هذه الحالة، قد يقوم طبيبك بتقليل الجرعة.</p><p dir="RTL">- إذا كنت تعاني من الصرع أو مرض باركنسون.</p><p dir="RTL">- إذا كنت تعاني من مرض السكري، أو إذا كان لديك عوامل خطر الإصابة بمرض السكري.</p><p dir="RTL">- إذا كان لديك تاريخ من فرط برولاكتين الدم )وجود كمية كبيرة جدًّا من البرولاكتين في الدم( أو ورم يعتمد على البرولاكتين )البرولاكتين هو هرمون يحفز إنتاج الحليب( على سبيل المثال: سرطان الثدي أو اضطرابات الغدة النخامية. ويضعك طبيبك تحت الملاحظة أثناء العلاج.</p><p dir="RTL">تم الإبلاغ عن مشاكل خطيرة في الكبد عند استخدام أميليان</p><p>&nbsp;</p><p dir="RTL">أبلغ طبيبك على الفور إذا شعرت بالتعب أو فقدان الشهية أو الغثيان أو القيء أو آلام في البطن أو اصفرار في العينين أو البشرة.</p><p dir="RTL">إذا أُصبت أثناء العلاج بتيبُّس في العضلات واضطرابات في الوعي، مع حُمَّى غير معروفة السبب، فتوقف عن العلاج فورًا واتصل بطبيبك على الفور.</p><p dir="RTL">إذا أُصبت أثناء العلاج باضطرابات في الرؤية أو صداع، فاستشر طبيبك بسرعة. إذا أُصبت بعدوى أو حمى غير مبررة، فقد يطلب منك طبيبك إجراء فحص دم على</p><p dir="RTL">الفور. وذلك لأن هذا الدواء قد يكون له تأثير على خلايا الدم لديك، أي قد يقلل عدد خلايا الدم البيضاء. يمكن رؤية هذه المشكلة في فحص الدم )انظر القسم 4، &laquo;الآثار الجانبية المحتملة.(&raquo;</p><p dir="RTL">لا ينبغي إيقاف العلاج بهذا الدواء فجأة؛ لأن هذا قد يُسبب متلازمة الانسحاب. ويتميز هذا بعلامات مثل الأرق والغثيان والقيء. وقد يُلاحَظ أيضًا حدوث حركات غير طبيعية وتكرار حدوث الاضطرابات الذهانية.</p><p>&nbsp;</p><p>الأطفال والمراهقون</p><p dir="RTL">- لا ينبغي إعطاء هذا الدواء للأطفال دون سن الـ 15 عامًا.</p><p dir="RTL">- لا يُنصَح باستخدام هذا الدواء للأطفال الذين تتراوح أعمارهم بين 15 و 18 عامًا.</p><p>&nbsp;</p><p>الأدوية الأخرى وأميليان</p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّ أدوية أخرى. يجب ألا تتناول هذا الدواء مع كابرجولين، أو كويناجولايد )دواء يُستخدم في علاج الاضطرابات في إفراز الحليب(، أو سيتالوبرام، أو اسيتالوبرام )أدوية تُستخدم في علاج القلق أو الاكتئاب(، أو دومبيريدون )دواء يُستخدم في علاج القيء والغثيان( أو هيدروكسيزين )دواء يُستخدم في علاج القلق أو الشرى( أو بيبيراكين )دواء يُستخدم في علاج الملاريا.(</p><p>&nbsp;</p><p>يجب عليك تجنُّب تناول هذا الدواء مع الأدوية التالية:</p><p dir="RTL">- بعض الأدوية المُستخدمة في علاج مرض باركينسون )أمانتادين، آبومورفين، بروموكربتين، إنتاكوبون، ليسوريد، بيرغوليد، بيريبيديل، براميبكسول، راساجيلين، روبينيرول، روتيجوتين، سيليجلين، تولكابون.(</p><p dir="RTL">- ليفودوبا.</p><p dir="RTL">- أوكسيبات الصوديوم )دواء يُستخدم في علاج داء النوم القهري.(</p><p dir="RTL">- بعض الأدوية التي قد تسبب اضطراب خطير في ضربات القلب )تُسمَّى &laquo;ضفيرة النتوءات(&raquo; مثل:</p><p dir="RTL">&bull; الأدوية المُستخدمة في علاج ضربات القلب غير المنتظمة )الفئة الأولى من مضادات اضطراب النُّظُم، مثل: الكوينيدين، والهيدروكينون والديسوبيرامايد والفئة الثالثة من مضادات اضطراب النظم مثل: الأميودارون والدرونيدارون والسوتالول والدوفيتيليد والايبيوتيليد.(</p><p>&bull; بعض الأدوية المستخدمة في علاج الاضطرابات النفسية )الكلوربرومازين، والسياميمازين، والدروبيريدول والفلوبينتكسول والفلوفينازين والهالوبيريدول والليفوميبرومازين والبيموزيد والبيبامبيرون والبيبوتيازين والسولبيريد والسلتوبرايد والتيابريد والزكلوبنثيكسول(</p><p dir="RTL">&bull; بعض الأدوية المضادة للطفيليَّات )الكلوروكين، والهالوفانترين، واللوميفانترين، والبينتاميدين(</p><p dir="RTL">&bull; دواء يُستخدم لعلاج الاعتماد على بعض الأدوية )الميثادون(</p><p dir="RTL">&bull; أدوية أخرى مثل: مركبات الزرنيخ، والديفيمانيل، والدولاسيترون عن طريق الوريد، والإيرثرومايسين عن طريق الوريد، وهيدروكسي كلوروكوين، والليفوفلوكساسين والهيدروكسي كلوروكين، والليفوفلوكساسين، والميكيوتازين والميزولاستين بروكالوبرايد، والفينكامين عن طريق الوريد، والموكسيفلوكساسين والسبيرامايسين عن طريق الوريد، والتوريميفين والفانديتانيب.</p><p dir="RTL">- الأدوية التي تحتوي على الكحول.</p><p>&nbsp;</p><p>أميليان مع الأطعمة والمشروبات والكحول</p><p dir="RTL">كما هو الحال مع جميع الأدوية المضادة للذهان في هذه المجموعة، يجب تجنُّب تناول المشروبات الكحولية أثناء العلاج.</p><p>&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">اطلبي النصيحة من الطبيب أو الصيدلي قبل تناول هذا الدواء إذا كنتِ حاملًا أو تقومين بالرضاعة الطبيعية أو تعتقدين أنك قد تكونين حاملًا أو تخططين لإنجاب طفل.</p><p>&nbsp;</p><p>الحمل</p><p dir="RTL">لا يُنصَح باستخدام أميليان أثناء الحمل أو بالنسبة للنساء في سن الإنجاب اللواتي لا يستخدمن وسائل منع الحمل الفعالة. فإذا كنت تستخدمين أميليان خلال الأشهر الثلاثة الأخيرة من الحمل، فقد يعاني طفلك من الهيجان أو زيادة تيبُّس العضلات أو الارتعاش اللاإرادي أو النعاس أو مشاكل في التنفُّس أو صعوبة في الرضاعة أو المص.</p><p dir="RTL">إذا كان طفلك يعاني من أيٍّ من هذه الأعراض، فاتصلي بطبيبك بسرعة.</p><p>&nbsp;</p><p>الرضاعة الطبيعية</p><p dir="RTL">يجب ألا تقومي بالرضاعة الطبيعية خلال فترة العلاج باستخدام أميليان. واستشيري طبيبك بشأن أفضل طريقة لتغذية طفلك إذا كنتِ تتناولين أميليان</p><p>&nbsp;</p><p>القيادة واستخدام الآلات</p><p dir="RTL">ينبغي عليك اتخاذ بعض الاحتياطات أثناء قيادة السيارة أواستخدام الآلات، حيث قد يسبب هذا الدواء الشعور بالنعاس أو تشوش الرؤية.</p><p>&nbsp;</p><p>أميليان يحتوي على اللاكتوز</p><p dir="RTL">يحتوي هذا الدواء على نوع من السكر )اللاكتوز( الذي يتحلل إلى جلاكتوز وجلوكوز. ويجب عدم استخدام هذا الدواء إذا كنت تعاني من عدم تحمُّل الجلاكتوز أو نقص اللاكتاز أو متلازمة سوء امتصاص الجلوكوز/ الجلاكتوز )أمراض وراثية نادرة.(</p><p dir="RTL">إذا أخبرك طبيبك أن لديك عدم تحمُّل لسكريات معينة، فاتصل/ي به قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا كما هو موضَّح في هذه النشرة، أو كما أخبرك الطبيب أو الصيدلي. وينبغي عليك أن تتحقّق من الطبيب أو الصيدلي إذا لم تكن متأكّدًا.</p><p dir="RTL">لا تُوقف العلاج من تلقاء نفسك.</p><p dir="RTL">يجب تناول هذا الدواء عن طريق الفم.</p><p dir="RTL">ابتلع القرص )الأقراص( مع كمية قليلة من الماء.</p><p>&nbsp;</p><p>إذا تناولت أميليان أكثر مما يجب</p><p dir="RTL">قد تشعر بالنعاس، والخدر )تأثير الاسترخاء(، وانخفاض في ضغط الدم، وأعراض خارج الهرمية )خاصّة الارتعاش وتيبُّس العضلات( أو قد تدخل في غيبوبة.</p><p dir="RTL">في حالة حدوث أيٍّ من هذه الأعراض، فمن الضروري للغاية أن تقوم أنت أو عائلتك/ أصدقاؤك بالاتصال بالطبيب أو الطوارىء.</p><p>&nbsp;</p><p>إذا نسيت تناول أميليان</p><p dir="RTL">لا تتناول جرعة مضاعفة للتعويض عن الجرعة المنسية. تناول جرعتك التالية في الوقت المحدد.</p><p dir="RTL">إذا نسيت تناول عدة جرعات، فاطلب النصيحة من طبيبك.</p><p>&nbsp;</p><p>إذا توقَفت عن تناول أميليان</p><p dir="RTL">لا يوجد معلومات.</p><p dir="RTL">إذا كانت لديك أي أسئلة بخصوص استخدام هذا الدواء، فاستشر الطبيب أو الممرض أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء بعض الآثار الجانبية، على الرغم من أن ذلك لا يحدث مع الجميع.</p><p dir="RTL">إذا أُصبت، أثناء العلاج، بتيبُّس في العضلات واضطرابات في الوعي، إلى جانب حمى غير مبررة، فأوقف العلاج فورًا واطلب العناية الطبية العاجلة.</p><p dir="RTL">الآثار الجانبية التالية شائعة جدًّا )تصيب أكثر من مريض واحد من كل :(10</p><p dir="RTL">رجفة، وتيبُّس عضلي، وتشنجات، وحركات غير طبيعية، وإفراز لعاب أكثر من المعتاد.</p><p>&nbsp;</p><p dir="RTL">الآثار الجانبية التالية شائعة )تصيب 1 إلى 10 مرضى من كل :(100</p><p dir="RTL">- تيبُّس الرقبة، أزمة تدوير المقلة )حركة غير طبيعية لبعض عضلات العين(، تقلُّص شديد في الفكّين.</p><p dir="RTL">- نعاس.</p><p dir="RTL">- أرق، وقلق، اهتياج.</p><p dir="RTL">- إمساك، وغثيان، وقيء، وجفاف الفم.</p><p dir="RTL">- برود جنسي )الافتقار إلى المتعة الجنسية لدى النساء.(</p><p dir="RTL">- فرط برولاكتين الدم )وجود الكثير من البرولاكتين، الهرمون الذي يحفّز إنتاج الحليب في الدم(، والذي قد يُسبب:</p><p dir="RTL">&bull; بالنسبة للنساء: غياب فترات الحيض، إنتاج غير طبيعي لحليب الثدي، ألم الثدي</p><p dir="RTL">&bull; عند الرجال: تورُّم الثديين، العجز الجنسي )صعوبة الانتصاب( - زيادة الوزن.</p><p dir="RTL">- انخفاض ضغط الدم. - تشوُّش الرؤية.</p><p>&nbsp;</p><p dir="RTL">الآثار الجانبية التالية غير شائعة )تصيب 1 إلى 10 مرضى من كل :(1000 - حركات لا إرادية في اللسان و/ أو الوجه.</p><p dir="RTL">- نوبات صرع )تقلصات لا إرادية لعضلة واحدة أو أكثر.( - ارتفاع السكر في الدم )فرط سكر الدم.(</p><p dir="RTL">- زيادة شحوم الدم )كثرة الدهون )الدهون الثلاثية( في الدم.( - فرط كوليسترول الدم )ارتفاع نسبة الكولسترول في الدم.( - بطء ضربات القلب.</p><p dir="RTL">- زيادة مستويات بعض إنزيمات الكبد، وخاصة ناقلات الأمين. - إصابة أنسجة الكبد.</p><p dir="RTL">- انخفاض كثافة العظام أو تغيُّر في بنية العظام )انخفاض الكثافة العظمية، هشاشة العظام(، ضعف العظام.</p><p dir="RTL">- ردود فعل تحسسيّة. - ارتباك.</p><p dir="RTL">- انسداد الأنف.</p><p dir="RTL">- اضطرابات الرئة )ذات الرئة الاستنشاقية( التي قد تظهر على شكل التهاب، وصعوبة في التنفس، وعدوى، وسعال )بشكل رئيسي مع الأدوية الأخرى التي لها تأثير اكتئابي عصبي مركزي.(</p><p dir="RTL">- ارتفاع ضغط الدم. - صعوبة التبوّل.</p><p dir="RTL">- قلة كريات الدم البيضاء، قلة العدلات )انظر القسم 2، الفقرة &laquo;التحذيرات والاحتياطات.(&raquo;</p><p>&nbsp;</p><p dir="RTL">الآثار الجانبية التالية نادرة )تصيب 1 إلى 10 مرضى من كل :(10000</p><p dir="RTL">- ندرة المحببات )انخفاض مستوى خلايا الدم البيضاء( )راجع القسم 2، &laquo;تحذيرات واحتياطات.(&raquo;</p><p dir="RTL">- ورم الغدة النخامية الحميد، والذي قد يسبب علامات مثل اضطرابات بصرية أو صداع. - انخفاض في كمية الصوديوم في الدم )نقص صوديوم الدم(، متلازمة الإفراز غير الملائم للهرمون المضاد لإدرار البول.</p><p dir="RTL">- حمى غير مبررة مع اضطرابات عامة وعصبية.</p><p dir="RTL">- إغماء شديد )فقدان للوعي(، اضطرابات في ضربات القلب من المحتمل قد تسبب الوفاة )انظر القسم .(2</p><p dir="RTL">- تورُّم وألم واحمرار في الساقين. وذلك لأن الجلطات الدموية في الأوردة )خاصة في الساقين( يمكن أن تنتقل عبر الأوعية الدموية لتصل إلى الرئتين؛ مما يسبب ألمًا في الصدر وصعوبة في التنفس.</p><p dir="RTL">- تورُّم مفاجئ في الوجه و/أو الرقبة يمكن أن يؤدي إلى صعوبة في التنفس، وقد يكون مهددًا للحياة )وذمة وعائية(، وبقع حمراء وحكّة على الجلد )طفح جلدي.(</p><p>&nbsp;</p><p dir="RTL">قد تظهر الأعراض الجانبية التالية، لكن تواترها غير معروف:</p><p dir="RTL">- أعراض الانسحاب لدى الأطفال الرُضّع )راجع القسم 2 &laquo;الحمل.(&raquo;</p><p dir="RTL">- متلازمة تململ الساقين )شعور بعدم الراحة في الساقين يزول مؤقتًا بالحركة، ويزداد سوءًا في نهاية اليوم.(</p><p dir="RTL">- زيادة حساسية الجلد عند التعرض للشمس والأشعة فوق البنفسجية. - السقوط بسبب فقدان التوازن؛ مما قد يؤدِّي إلى حدوث كسور.</p><p>&nbsp;</p><p>الإبلاغ عن الآثار الجانبية</p><p dir="RTL">إذا عانيت من أيِّ آثارٍ جانبية، فتحدَّث إلى طبيبك أو الممرضة أو الصيدلي. ويتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء صلاحيته المدوّن على العبوة. ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&bull; يُحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. واسأل طبيبك عن كيفية التخلص من الأدوية التي لم يعد لها استخدام. وسوف تساعد تلك التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يحتوي أميليان على:</strong></p><p dir="RTL">المادة الفعّالة هي أميسولبرايد.</p><p dir="RTL">كل قرص أميليان 100 ملغ يحتوي على 100 ملغ أميسولبرايد. كل قرص أميليان 200 ملغ يحتوي على 200 ملغ أميسولبرايد. كل قرص أميليان 400 ملغ يحتوي على 400 ملغ أميسولبرايد.</p><p dir="RTL"><strong>المكونات</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>هي</strong><strong>:</strong></p><p dir="RTL">سليلوز دقيق التبلور لاكتوز&nbsp; مونوهيدرات غليكولات النشاء الصودي هيدروكسي ميثيل سيليولوز سترات المغنيسيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو أميليان، ومحتويات العبوة</p><p dir="RTL"><strong>أميليان</strong><strong> أقراص </strong><strong>400</strong><strong> ملغ</strong><strong>:</strong> أقراص على شكل كبسولة، ذات لون أبيض إلى أبيض مائل<strong> </strong>للصفرة، غير مُغلّفة، ومحدبة من الجهتين، محززة من أحد الجانبين وبلا أي نقوش على الجانب الآخر.</p><p dir="RTL"><strong>أميليان أقراص </strong><strong>200</strong><strong> ملغ</strong><strong>:</strong> أقراص مستديرة مسطحة الوجه، ذات لون أبيض إلى أبيض مائل<strong> </strong>للصفرة، محززة من أحد الجانبين وبلا أي نقوش على الجانب الآخر.</p><p>&nbsp;</p><p dir="RTL"><strong>أميليان أقراص </strong><strong>100</strong><strong> ملغ</strong><strong>:</strong> أقراص مستديرة مسطحة الوجه، ذات لون أبيض إلى أبيض مائل<strong> </strong>للصفرة، بلا أي نقوش على الجانبين.</p><p><strong>أميليان 100 ملغ و200 ملغ و400 ملغ</strong> متاح في عبوة تحتوي على 30 قرصًا.<strong> </strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة حاملة </strong><strong>حقوق التسويق والمُصنّعة:</strong></p><p dir="RTL">شركة الشرق الأوسط للصناعات الدوائية )أفالون فارما(</p><p dir="RTL">ص.ب. 4180 الرياض 11491، المملكة العربية السعودية المدينة الصناعية الثانية، الرياض</p><p dir="RTL">هاتف: 2653427 - 2653448 (11) 00966</p><p dir="RTL">فاكس: 2654723 (11) 00966</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في 2024/05


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amilian 100 mg Tablets
Amilian 200 mg Tablets
Amilian 400 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Amilian 100 mg tablet contains 100 mg of Amisulpride.
Each Amilian 200 mg tablet contains 200 mg of Amisulpride.
Each Amilian 400 mg tablet contains 400 mg of Amisulpride.

Amilian 100 mg tablet contains lactose monohydrate 32.5625 mg per tablet.
Amilian 200 mg tablet contains lactose monohydrate 65.125 mg per tablet.
Amilian 400 mg tablet contains lactose monohydrate 130.25 mg per tablet.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.

Amilian 100 mg Tablets: White to off-white, round flat faced uncoated tablet plain on both sides.
Amilian 200 mg Tablets: White to off-white, round flat faced uncoated tablet scored on one side and plain on other side.
Amilian 400 mg Tablets: White to off-white, Capsule shape, biconcave uncoated tablets scored on one side and plain on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.</p><p>Amisulpride also regulates secondary negative symptoms in productive state, as well as affective disorders such as depressive mood.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For acute psychotic episodes, oral doses between 400 mg/day and 800 mg/day are recommended. In individual cases, the daily dose may be increased up to 1200 mg/day. Doses above 1200 mg/day have not been extensively evaluated for safety and therefore should not be used. No</p><p>specific titration is required when initiating the treatment. Doses should be adjusted according to individual response.</p><p>For patients with mixed positive and negative symptoms, doses should be adjusted to obtain optimal control of positive symptoms.</p><p>Maintenance treatment should be established individually with the minimally effective dose.</p><p>For patients characterised by predominant negative symptoms (deficit syndrome), oral doses between 50 mg/day and 300 mg/day are recommended. Doses should be adjusted individually.</p><p>Amisulpride can be administered once a day at oral doses up to 400mg, higher dose should be split into two separate doses.</p><p>Elderly: The safety of amisulpride has been examined in a limited number of elderly patients. Amisulpride should be used with particular caution because of a possible risk of hypotension and sedation. Reduction in dosage may also be required because of renal insufficiency.</p><p>Children: The efficacy and safety of amisulpride from puberty to the age of 18 years have not been established. There are limited data available on the use of amisulpride in adolescents in schizophrenia. Therefore, the use of amisulpride from puberty to the age of 18 years is not recommended; in children up to puberty amilsulpride is contraindicated as its safety has not yet been established.</p><p>Renal insufficiency: Amisulpride is eliminated by the renal route. In renal insufficiency, the dose should be reduced to half in patients with creatinine clearance (CRCL) between 30-60 ml/min and to a third in patients with CRCL between 10-30 ml/min.</p><p>As there is no experience in patients with severe renal impairment (CRCL &lt; 10 ml/min) particular care is recommended in these patients (see section 4.4 Special Warnings and Special Precautions for Use).</p><p>Hepatic insufficiency: since the drug is weakly metabolised a dosage reduction should not be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active ingredient or to other ingredients of the product.

Concomitant prolactin-dependent tumours (e.g. pituitary gland prolactinomas or breast cancer) (see section 4.4 and section 4.8).

Phaeochromocytoma.

Children up to puberty.

Combination with levodopa (see section 4.5 Interactions with other medicinal products and other forms of interactions).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other neuroleptics, neuroleptic malignant syndrome (NMS) may occur. This condition is characterised by high fever, muscle rigidity, autonomic dysfunction, clouding of consciousness, rhabdomyolysis and elevated CPK values, and it is potentially fatal. If a patient develops signs and symptoms indicative for NMS or presents with unexplained hyperthermia, particularly at high daily doses, all antipsychotic agents including amisulpride must be discontinued.</p><p>Rhabdomyolysis has also been observed in patients without Neuroleptic Malignant Syndrome.</p><p>Hyperglycaemia has been reported in patients treated with some atypical antipsychotic agents, including amisulpride, therefore patients with an established diagnosis of diabetes mellitus or with risk factors for diabetes who are started on amisulpride, should get appropriate glycemic monitoring.</p><p>Amisulpride is eliminated by the renal route. In cases of renal insufficiency, the dose should be decreased or intermittent treatment could be considered (see section 4.2 Posology and method of administration).</p><p>Severe liver toxicity has been reported with amisulpride use. Patients should be instructed to report immediately signs such as asthenia, anorexia, nausea, vomiting, abdominal pain or icterus to a physician. Investigations including clinical examination and biological assessment of liver function should be undertaken immediately (see section 4.8)</p><p>Amisulpride may lower the seizure threshold. Therefore patients with a history of epilepsy should be closely monitored during amisulpride therapy.</p><p>In elderly patients, amisulpride, like other neuroleptics, should be used with particular caution because of a possible risk of hypotension and sedation. Reduction in dosage may also be required because of renal insufficiency.</p><p>As with other antidopaminergic agents, caution should be also exercised when prescribing amisulpride to patients with Parkinson&rsquo;s disease since it may cause worsening of the disease. Amisulpride should be used only if neuroleptic treatment cannot be avoided.</p><p>Prolongation of the QT interval</p><p>Caution should be exercised when amisulpride is prescribed in patients with known cardiovascular disease or family history of QT prolongation, and concomitant use with neuroleptics should be avoided.</p><p>Stroke:</p><p>In randomised clinical trials versus placebo performed in a population of elderly patients with dementia and treated with certain atypical antipsychotic drugs, a 3-fold increase of risk of cerebrovascular events has been observed. The mechanism of such risk increase is not known. An increase in the risk with other antipsychotic drugs, or other populations of patients cannot be excluded. Amisulpride should be used with caution in patients with stroke risk factors.</p><p>Withdrawal symptoms including nausea, vomiting and insomnia have been described after abrupt cessation of high therapeutic doses of antipsychotic drugs. Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinsia) has been reported with amisulpride. Therefore, gradual withdrawal of amisulpride is advisable.</p><p>Leukopenia, neutropenia and agranulocytosis have been reported with antipsychotics, including Amilian. Unexplained infections or fever may be evidence of blood dyscrasia (see Section 4.8), and requires immediate haematological investigation.</p><p>Elderly patients with dementia:</p><p>Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug- treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5% compared to a rate of 2.6% in the placebo group. Although the causes of death in clinical trials with atypical antipsychotics were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature.</p><p>Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality.</p><p>The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.</p><p>Breast cancer:</p><p>Amisulpride causes an increase in plasma prolactin levels. Therefore, caution should be exercised and patients with a history or a family history of breast cancer should be closely monitored during amisulpride therapy. Amisulpride is contraindicated in patients with breast cancer (see section 4.3 and 4.8).</p><p>Venous thromboembolism:</p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with amisulpride and preventative measures undertaken.</p><p>Benign pituitary tumour:</p><p>Amisulpride may increase prolactin levels. Cases of benign pituitary tumours such as prolactinoma have been observed during amisulpride therapy. In case of very high levels of prolactin or clinical signs of pituitary tumour (such as visual field defect and headache), pituitary imaging should be performed. If the diagnosis of pituitary tumour is confirmed, the treatment with amisulpride must be stopped.</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Sodium:</p><p>Amilian 100 mg tablet contains 8.625 mg sodium per tablet.</p><p>Amilian 200 mg tablet contains 17.250 mg sodium per tablet.</p><p>Amilian 400 mg tablet contains 34.50 mg sodium per tablet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CONTRAINDICATED COMBINATIONS</p><p>Levodopa reciprocal antagonism of effects between levodopa and neuroleptics.</p><p>COMBINATIONS NOT RECOMMENDED</p><p>Amisulpride may enhance the central effects of alcohol.</p><p>COMBINATIONS TO BE TAKEN INTO ACCOUNT</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CNS depressants including narcotics, anaesthetics, analgesics, sedative H1 antihistamines, barbiturates, benzodiazepines and other anxiolytics, clonidine and derivatives.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antihypertensive drugs and other hypotensive medications.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Co-administration of amisulpride and clozapine may lead to an increase in plasma levels of amisulpride.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution is advised when prescribing amisulpride with medicines known to prolong the QT interval, e.g., class IA antiarrythmics (e.g., quinidine, disopyramide) and class III antiarrhytmics (e.g., amiodarone, sotalol), some antihistaminics, some other antipsychotics and some antimalarials (e.g., mefloquine) (see section 4.4)</p><p>Amisulpride may oppose the effect of dopamine agonists e.g. bromocriptine, ropirinole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There are only limited data available from the use of amisulpride in pregnant women. The safety of amisulpride during human pregnancy has not been established.</p><p>Amisulpride crosses the placenta.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>The use of amisulpride is not recommended during pregnancy and in women of child bearing potential not using effective contraception, unless the benefits justify the potential risks.Neonates exposed to antipsychotics, including Amilian, during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery (see Section 4.8). There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.</p><p>Consequently, newborns should be monitored carefully.</p><p>Breast-feeding</p><p>Amisulpride is excreted into breastmilk in rather large amounts above the accepted value of 10% of the maternal weight-adjusted dosage in some cases, but blood concentrations in breastfed infants have not been evaluated. There is insufficient information on the effects of amisulpride in newborns/infants. A decision must be made whether to discontinue breast-feeding or to abstain from amisulpride therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.</p><p>Fertility</p><p>A decrease in fertility linked to the pharmacological effects of the drug (prolactinmediated effect) was observed in treated animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Even when used as recommended, amisulpride may cause somnolence and blurred vision so that the ability to drive vehicles or operate machinery can be impaired (see section 4.8 Undesirable Effects).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Adverse effects have been ranked under headings of frequency using the following convention: very common (</em>&ge; <em>1/10); common (</em>&ge; <em>1/100; &lt;1/10); uncommon (</em>&ge; <em>1/1,000;&lt;1/100); rare (</em>&ge; <em>1/10,000;&lt;1/1,000); very rare (&lt;1/10,000), frequency not known (cannot be estimated from the available data).</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood and lymphatic system disorders:</p><p><strong>Uncommon: </strong>leukopenia, neutropenia (see Section 4.4).</p><p><strong>Rare: </strong>agranulocytosis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immune system disorders:</p><p><strong>Uncommon: </strong>allergic reaction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Endocrine disorders:</p><p><strong>Common: </strong>amisulpride causes an increase in plasma prolactin levels which is reversible after drug discontinuation. This may result in galactorrhoea, amenorrhoea, gynaecomastia, breast pain, and erectile dysfunction.</p><p><strong>Rare: </strong>benign pituitary tumour such as prolactinoma (see Section 4.4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metabolism and nutrition disorders:</p><p><strong>Uncommon: </strong>hyperglycemia, hypertriglyceridemia and hypercholesterolemia.</p><p><strong>Rare: </strong>hyponatraemia, syndrome of inappropriate antidiuretic hormone secretion (SIADH).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psychiatric disorders:</p><p><strong>Common: </strong>insomnia, anxiety, agitation, orgasmic dysfunction.</p><p><strong>Uncommon: </strong>confusion.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervous system disorders:</p><p><strong>Very common: </strong>extrapyramidal symptoms may occur: tremor, rigidity, hypokinesia, hypersalivation, akathisia, dyskinesia. These symptoms are generally mild at optimal dosages and partially reversible without discontinuation of amisulpride upon administration of antiparkinsonian medication. The incidence of extrapyramidal symptoms which is dose related, remains very low in the treatment of patients with predominantly negative symptoms with doses of 50-300 mg/day.</p><p><strong>Common: </strong>acute dystonia (spasm torticollis, oculogyric crisis, trismus) may appear. This is reversible without discontinuation of amisulpride upon treatment with an antiparkinsonian agent. Somnolence.</p><p><strong>Uncommon: </strong>tardive dyskinesia characterized by rhythmic, involuntary movements primarily of the tongue and/or face have been reported, usually after long term administration. Antiparkinsonian medication is ineffective or may induce aggravation of the symptoms.</p><p>Seizures.</p><p><strong>Rare: </strong>Neuroleptic Malignant Syndrome (see Section 4.4), which is a potentially fatal complication.</p><p><strong>Not known: </strong>restless legs syndrome.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Eye disorders:</p><p><strong>Common: </strong>blurred vision.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac disorders:</p><p><strong>Uncommon: </strong>bradycardia.</p><p><strong>Rare: </strong>QT interval prolongation, ventricular arrhythmias such as torsade de pointes, ventricular tachycardia, ventricular fibrillation, cardiac arrest, sudden death (see Section 4.4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vascular disorders:</p><p><strong>Common: </strong>hypotension.</p><p><strong>Uncommon: </strong>increase in blood pressure.</p><p><strong>Rare: </strong>venous thromboembolism, including pulmonary embolism, sometimes fatal, and deep vein thrombosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory, thoracic and mediastinal disorders:</p><p><strong>Uncommon: </strong>nasal congestion, aspiration pneumonia (mainly in association with other antipsychotics and CNS depressants).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal disorders:</p><p><strong>Common: </strong>constipation, nausea, vomiting, dry mouth.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatobilary disorders:</p><p><strong>Uncommon: </strong>hepatocellular injury</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and subcutaneous tissue disorders:</p><p><strong>Rare: </strong>angioedema, urticaria.</p><p><strong>Not known: </strong>photosensitivity reaction.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Musculoskeletal and connective tissue disorders:</p><p><strong>Uncommon: </strong>osteopenia, osteoporosis.</p><p><strong>Not known: </strong>rhabdomyolysis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal and urinary disorders:</p><p><strong>Uncommon: </strong>urinary retention</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy, puerperium and perinatal conditions</p><p><strong>Frequency not known: </strong>drug withdrawal syndrome neonatal (see Section 4.6)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injury, poisoning and procedural complications:</p><p><strong>Not known: </strong>fall as a consequence of adverse reactions compromising body balance.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investigations:</p><p><strong>Common: </strong>weight gain.</p><p><strong>Uncommon: </strong>elevations of hepatic enzymes, mainly transaminases.</p><p><strong>Not known: </strong>blood creatine phosphokinase increased.</p><p><img src="data:image/png;base64,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" alt="" width="609" height="295" vspace="0" hspace="0" border="0" style="width:609px;height:295px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience with amisulpride in overdosage is limited. Exaggeration of the known pharmacological effects of the drug has been reported. These include drowsiness, sedation, hypotension, extrapyramidal symptoms and coma. Fatal outcomes have been reported mainly in combination with other psychotropic agents.</p><p>In cases of acute overdosage, the possibility of multiple drug intake should be considered. Since amisulpride is weakly dialysed, haemodialysis is of no use to eliminate the drug.</p><p>There is no specific antidote to amisulpride. Appropriate supportive measures should therefore be instituted: close supervision of vital functions and cardiac monitoring (risk of prolongation of QT interval) until the patient recovers.</p><p>If severe extrapyramidal symptoms occur, anticholinergic agents should be administered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antipsychotics, psychopharmaca, neuroleptics ATC code: N05A L05.</p><p>Amisulpride binds selectively with a high affinity to human dopaminergic D2/D3 receptor subtypes whereas it is devoid of affinity for D1, D4 and D5 receptor subtypes.</p><p>Unlike classical and atypical neuroleptics, amisulpride has no affinity for serotonin, &alpha;- adrenergic, histamine H1 and cholinergic receptors. In addition, amisulpride does not bind to sigma sites.</p><p>In animals, at high doses it blocks post-synaptic D2 receptors located in the limbic structures in preference to those in the striatum. Unlike classical neuroleptics it does not induce catalepsy and hypersensitivity of D2 dopamine receptors does not develop after repeated treatment. At low doses it preferentially blocks pre-synaptic D2/D3 receptors, producing dopamine release responsible for its disinhibitory effects.</p><p>This atypical pharmacological profile may explain amisulpride&rsquo;s antipsychotic effect at higher doses through post-synaptic dopamine receptor blockade and its efficacy against negative symptoms, at lower doses, through pre-synaptic dopamine receptor blockade. In addition, the reduced tendency of amisulpride to produce extrapyramidal side effects may be related to its preferential limbic activity.</p><p>In clinical studies including schizophrenic patients with acute exacerbations, amisulpride significantly alleviated secondary negative symptoms as well as affective symptoms such as depressed mood.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In man, amisulpride shows two absorption peaks: one which is attained rapidly, one hour post- dose and a second between 3 and 4 hours after administration.</p><p>Corresponding plasma concentrations are 39 &plusmn; 3 and 54 &plusmn; 4 ng/ml after a 50 mg dose.</p><p>The volume of distribution is 5.8 l/kg. A plasma protein binding is low (16%) drug interactions are unlikely.</p><p>Absolute bioavailability is 48%. Amisulpride is weakly metabolised : two inactive metabolites, accounting for approximately 4% of the dose, have been identified. There is no accumulation of amisulpride and its pharmacokinetics remain unchanged after the administration of repeated doses. The elimination half-life of amisulpride is approximately 12 hours after an oral dose.</p><p>Amisulpride is eliminated unchanged in the urine. Fifty percent of an intravenous dose is excreted via the urine, of which 90% is eliminated in the first 24 hours. Renal clearance is in the order of 20 l/h or 330 ml/min.</p><p>Kinetic profile of amisulpride is not influenced by diet.</p><p>A carbohydrate rich meal (containing 68% fluids) significantly decreases the AUCs, Tmax and Cmax of amisulpride but no changes were seen after a high fat meal.</p><p>However, the significance of these findings in routine clinical use is not known.</p><p>Hepatic insufficiency: since the drug is weakly metabolised a dosage reduction should not be necessary in patients with hepatic insufficiency.</p><p>Renal insufficiency: The elimination half-life is unchanged in patients with renal insufficiency while systemic clearance is reduced by a factor of 2.5 to 3. The AUC of amisulpride in mild renal failure increased two fold and almost tenfold in moderate renal failure (see section 4.2 for dosing recommendations). Experience is however limited and there is no data with doses greater than 50 mg.</p><p>Amisulpride is very weakly dialysed.</p><p>Limited pharmacokinetic data in elderly subjects (&gt; 65 years) show that a 10-30 % rise occurs in Cmax, T1/2 and AUC after a single oral dose of 50 mg. No data are available after repeat dosing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An overall review of the completed safety studies indicates that amisulpride is devoid of any general, organ-specific, teratogenic, mutagenic or carcinogenic risk. Changes observed in rats</p><p>and dogs at doses below the maximum tolerated dose are either pharmacological effects or are devoid of major toxicological significance under these conditions. Compared with the maximum recommended dosages in man, maximum tolerated doses are 2 and 7 times greater in the rat (200 mg/kg/day) and dog (120 mg/kg/day) respectively in terms of AUC. No carcinogenic risk, relevant to man, was identified in mice (up to 120mg/kg/day) and in rats (up to 240mg/kg/day), corresponding for the rat to 1.5 to 4.5 times the expected human AUC.</p><p>Reproductive studies performed in rats, rabbits and mice did not show any teratogenic potential.</p><p>In animal trials, amisulpride elicited an effect on foetal growth and development at doses corresponding to Human Equivalent Dose of 2000 mg/day and upwards for a 50-kg patient. There was no evidence for a teratogenic potential of amisulpride.</p><p>Studies on the impact of amisulpride on the behaviour of the offspring have not been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Microcrystalline cellulose</li><li>Lactose monohydrate</li><li>Sodium starch Glycolate</li><li>Hydroxypropyl Methyl cellulose</li><li>Magnesium Stearate</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p><p>No special precautions for storage</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets are packed in clear Alu-PVC / PVDC 250 &micro;m/ 60 GSM blister.</p><p>Pack sizes: 30 Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special precautions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Middle East Pharmaceutical Industries Company (Avalon-Pharma)
8146 King Muhammad V, Sulimaniyah, RIYADH 12223 - 3904 P.O. Box 4180, Riyadh 11491, Kingdom of Saudi Arabia
Tel: 920010564, Fax: +966114629288


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>